Testimony before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Desmopressin for Nocturia
Public Citizen strongly opposes Food and Drug Administration (FDA) approval of Nocdurna (desmopressin) — a drug already twice rejected by the FDA — for treatment of nocturia due to nocturnal polyuria in adults because the drug’s serious risks far outweighs its meager clinical benefits.